Compare Crowdstrike Holdings Inc (CRWD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Medpace Holdings Inc — how do they compare? Crowdstrike Holdings Inc trades at $275.16 (market cap $269.31B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Crowdstrike Holdings Inc is far larger — about 16× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 9,381,560). Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Medpace Holdings Inc for 14 Days on average.
| CRWD | MEDP | |
|---|---|---|
Market Cap | $269.31B | $16.82B |
Volume | 9,381,560 | 223,093 |
Sector | Technology | Health |
52-Week High | $278.86 | $630.19 |
52-Week Low | $87.56 | $393.42 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $265.11B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $272.00, up 2.47% today and near its all-time highs, with strong technical momentum and bullish moving average signals. The company demonstrates impressive revenue growth, reaching $3.95 billion in 2025, though profitability remains volatile with a net income margin of -0.49%. Recent quarterly earnings have consistently beaten expectations, and analyst sentiment remains overwhelmingly positive with 76% buy ratings.
The outlook for CRWD remains favorable given strong cybersecurity demand and AI-driven growth opportunities, though elevated valuation multiples and competitive pressures present risks. Wall Street's consensus price target of $235.74 suggests potential downside from current levels, but continued execution on revenue growth and margin expansion could support further upside.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
